Combination of decay-accelerating factor expression and α1,3- galactosyltransferase knockout affords added protection from human complement-mediated injury

Transplantation

Volumn 64, Issue 6, 1997, Pages 882-888

  Van Denderen, Bryce J W ^a,b   Salvaris, Evelyn ^a   Romanella, Margarita ^a   Aminian, Atousa ^a   Katerelos, Marina ^a   Tange, Margaret J ^a   Pearse, Martin J ^a   D'Apice, Anthony J F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; DECAY ACCELERATING FACTOR; EPITOPE; GALACTOSYLTRANSFERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOLYSIS; ENZYME ACTIVITY; GENE EXPRESSION; HEART PERFUSION; HOMOZYGOSITY; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SWINE; TRANSGENIC ANIMAL;

ANIMALS; ANTIGENS, CD31; ANTIGENS, CD55; CELL SURVIVAL; CELLS, CULTURED; COMPLEMENT C3; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM, VASCULAR; EPITOPES; GALACTOSYLTRANSFERASES; HOMOZYGOTE; HUMANS; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIUM; SPLEEN; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030846072     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199709270-00016     Document Type: Article

References (22)

1. Cooper DKC, Ye Y, Rolf JLL, Zuhdi N. The pig as a potential organ donor for man. In: Cooper DKC, Kemp E, Reemtsma K, White DJG, eds. Xenotransplantation. Heidelberg: Springer-Verlag, 1991: 481.
2. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
3. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
4. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. Transplantation of discordant xenografts: a challenge revisited. Immunol Today 1996; 17: 373.
5. Winkler H, Ferran C, Bach FH. Accommodation of xenografts: a concept revisited. Xenotransplantation 1995; 2: 53.
6. Platt JL, Logan JS. Use of transgenic animals in xenotransplantation. Transplant Rev 1996; 10: 69.
7. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
8. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay-accelerating factor (DAF), in transgenic pigs: a potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325.
9. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate xenografts from humoral injury. Nat Med 1995; 1: 423.
10. Hume DM, Merrill JP, Miller BF et al. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955; 34: 327.
11. Sandrin MS, McKenzie IFC. Gal α(1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 1994; 141: 169.
12. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α1-3)gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
13. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153: 3791.
14. Tearle RG, Tange MJ, Zannettino ZL, et al. The α-1,3-galactosyltransferase knockout mouse: implications for xenotransplantation. Transplantation 1996; 61: 13.
15. Sandrin MS, Fodor WL, Mouhtouris E, et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med1995; 1: 1261.
16. Chen C-G, Fisicaro N, Shinkel TA, et al. Reduction in gal-α1,3-gal epitope expression in transgenic mice expressing human H-transferase. Xenotransplantation 1996; 3: 69.
17. van Denderen BJW, Pearse MJ, Katerelos M, et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996; 61: 582.
18. Coyne KE, Hall SE, Thompson ES, et al. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay-accelerating factor. J Immunol 1992; 149: 2906.
19. Harrison RA, Lachmann PJ. Complement Technology. In: Weir DM, Herzenberg LA, Blackwell C, eds. Handbook of experimental immunology and immunohistochemistry, Vol. 39. Oxford: Blackwell Scientific Publications, 1986: 1.
20. Servais G, Walmagh J, Duchateau J. Simple quantitative hemolytic microassay for determination of complement alternative pathway activation (AP50). J Immunol Methods 1991; 140: 93.
21. Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxsmal nocturnal hemoglobinuria. J Exp Med 1985; 162: 75.
22. Cowan PJ, Shinkel TA, Witort EJ, Barlow H, Pearse MJ, d'Apice AJF. Targeting gene expression to endothelial cells in transgenic mice using the human ICAM-2 promoter. Transplantation 1996-62: 155.